BRTX:NSD-BioRestorative Therapies Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.00

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

0.01M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


BRTX Stock Forecast & Price:
Based on the BioRestorative Therapies Inc stock forecasts from 0 analysts, the average analyst target price for BioRestorative Therapies Inc is not available over the next 12 months. BioRestorative Therapies Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioRestorative Therapies Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, BioRestorative Therapies Inc’s stock price was USD 3.00. BioRestorative Therapies Inc’s stock price has changed by -10.45% over the past week, -0.99% over the past month and -80.77% over the last year.

About BioRestorative Therapies Inc (BRTX:NSD)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/ ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

USD75.53B 24.40 16.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD68.27B 12.89 9.72
MRNA Moderna Inc

N/A

USD66.97B 5.32 3.83
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.59B 3.11 1.77
SGEN Seagen Inc

N/A

USD31.38B 55.02 -46.75
RPRX Royalty Pharma Plc

N/A

USD29.88B 43.33 20.93
ALNY Alnylam Pharmaceuticals Inc

N/A

USD28.07B N/A -36.52
GMAB Genmab AS

N/A

USD24.11B 75.33 6.42
ARGX argenx NV ADR

N/A

USD20.75B N/A -20.02

ETFs Containing BRTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.88% 56% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.88% 56% F 34% F
Trailing 12 Months  
Capital Gain -80.77% 14% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.77% 14% F 10% F
Trailing 5 Years  
Capital Gain -99.98% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.98% 1% F N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1,054.55% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,054.55% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 2,448.09% 1% F 1% F
Risk Adjusted Return 43.08% 84% B 76% C
Market Capitalization 0.01B 4% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.54 90% A- 93% A
Price / Cash Flow Ratio -3.24 50% F 65% D
EV/EBITDA 0.25 24% F 52% F
Management Effectiveness  
Return on Equity -383.30% 7% F 3% F
Return on Invested Capital -394.39% 3% F 4% F
Return on Assets -82.79% 5% F 2% F
Debt to Equity Ratio 0.88% 84% B 87% B+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.97 62% D- 56% F
Short Percent 1.51% 72% C- 66% D
Beta 70.37 0% N/A 0% N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector